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Thrombotic thrombocytopenic purpura (TTP) is a critical complication of treatment with 
mitomycin C. We retrospectively describe the case of a patient with progressive renal 
cell carcinoma and mitomycin-induced TTP refractory to plasma exchange and glucocorti-
coids; we describe the clinical course, successful management of TTP with rituximab, 
and follow-up of this case. Mitomycin-induced TTP resolved completely by a total of 4 
infusions of rituximab 375 mg/m
2 on a weekly basis, and it took up to 12 months to obtain 
a platelet count of ＞100,000/μL. Rituximab is indicated for the treatment of mitomycin-in-
duced TTP refractory to plasma exchange and glucocorticoids, and it could improve the 
patient’s quality of life despite the presence of underlying malignancy.
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INTRODUCTION
  Thrombotic thrombocytopenic purpura (TTP) is a syn-
drome characterized by microangiopathic hemolytic anemia, 
thrombocytopenia, acute renal insufficiency, neurologic ab-
normalities, and fever. It is diagnosed primarily by the pres-
ence of microangiopathic hemolytic anemia and thrombocy-
topenia [1]. Although many cases of TTP are idiopathic, 
a variety of causes have been identified. Some chemo-
therapeutic agents, including mitomycin C (MMC), have 
been involved in TTP, and direct endothelial injury is the 
initiating event in these settings [2]. Chemotherapeutic 
agent-induced TTP is often refractory to standard treatments 
such as plasma exchange. We present a case of mitomycin-in-
duced TTP refractory to prolonged plasma exchange and 
methylprednisolone; the patient was successfully treated 
with rituximab, an anti-CD20 monoclonal antibody.
CASE REPORT
  A 56-year-old man with renal cell carcinoma was admitted 
to our hospital for the evaluation of dyspnea and pretibial 
edema, which he had for 2 weeks. Renal cell carcinoma 
was diagnosed about 3 years ago when he had undergone 
left radical nephrectomy. Ten months after the nephrectomy, 
multiple hematogenous metastases had been found in both 
the lungs, and he had received salvage chemotherapy with 
aldesleukin, 5-fluorouracil (5-FU), interferon alfa-2b (IFN-α- 
2b), sorafenib, and MMC for 1 year; in particular, MMC 
9 mg was administered intravenously 10 times over 3 months 
until 2 months before this admission. 
  On admission, the patient’s vital signs were stable; fever 
was absent; and he was alert and oriented. Laboratory data 
showed that the Hb level was 9.2 g/dL; platelet count, 
36,000/μL; WBC count, 6,160/μL; blood urea nitrogen (BUN) 
level, 38.9 mg/dL; creatinine level, 2.4 mg/dL; international 
normalized ratio (INR, which indicated the prothrombin 
time [PT]), 1.26; activated partial thromboplastin time 
(aPTT), 33.5 sec; fibrinogen level, 411 mg/dL; and D-dimer Korean J Hematol 2011;46:45-8.
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Fig. 1. Peripheral blood smear (Wright stain, x1,000) showing schisto-
cytes and spherocytes.
Fig. 2. Change of platelet and schistocyte count during 
the treatment period.
level, 1.52 μg/mL. On hospital day (HD) 4, his dyspnea ex-
acerbated, and he developed cough with blood-tinged spu-
tum and fever with body temperature of up to 38.5
oC. 
Laboratory data showed that the Hb level was 7.7 g/dL; 
platelet count, 27,000/μL; WBC count, 9,860/μL; BUN level, 
32.2 mg/dL; creatinine level, 2.2 mg/dL; and lactic de-
hydrogenase (LDH) level, 629 IU/L; further, antinuclear and 
antineutrophil cytoplasmic antibodies (ANCA) were absent. 
A peripheral blood smear revealed a marked decrease in 
the number of platelets (no clumping was noted) and moder-
ate degree of anisopoikilocytosis with a significant number 
of schistocytes and spherocytes per high power field (Fig. 
1). On HD 5, he was intubated and ventilated because of 
respiratory failure resulting from pulmonary edema and 
hemorrhage. From the same day, he underwent daily plasma-
pheresis under the diagnosis of TTP; however, his clinical 
course did not improve. From HD 12, in addition to daily 
plasmapheresis, methylprednisolone 125 mg was administered 
intravenously twice a day because the patient did not respond 
to plasmapheresis alone. Laboratory data showed that the 
Hb level was 11.6 g/dL (with intermittent RBC transfusion); 
platelet count, 21,000/μL; WBC count, 10,400/μL; retic-
ulocyte count, 3.79%; BUN level, 48.5 mg/dL; creatinine 
level, 3.4 mg/dL; LDH level, 1,075 IU/L; INR, 1.4; aPTT, 
43.2 sec; fibrinogen level, 496 mg/dL; D-dimer level, 2.23 
μg/mL; and haptoglobin level, ＜10 mg/dL. A blood smear 
revealed marked anisopoikilocytosis, with 11 schistocytes/ 
high power field. During the next 8 days, he did not respond 
clinically to plasmapheresis plus methylprednisolone therapy. 
On HD 20, in addition to daily plasmapheresis and methyl-
prednisolone, rituximab 375 mg/m
2 was administered intra-
venously; thereafter, rituximab was administered 3 times 
more at weekly intervals (Fig. 2). Meanwhile, plasmapheresis 
was performed on alternate days, during HD 24-30; by HD 
30, plasmapheresis was performed 19 times and was dis-
continued. On HD 25, the patient was extubated, and he 
has been mentally alert since then. Until HD 55, he required 
platelet transfusion almost every other day to maintain a 
platelet count of ≥10,000/μL; thereafter, the count was main-
tained above 10,000/μL without further platelet transfusion. 
Moreover, until HD 29, RBC was transfused almost every 
other day to maintain a Hb level of ＞8 g/dL, but subsequently, 
the RBC transfusion interval was progressively extended un-
til transfusion was performed once a week. The LDH level 
normalized 5 months after rituximab administration.
  The creatinine level progressively increased up to 7.0 mg/ 
dL during the 12-month follow-up period. This progressive 
renal dysfunction was likely to be associated with underlying 
diseases such as renal cell carcinoma, diabetes mellitus, hy-
pertension, and drug toxicity. On HD 74, prednisolone ther-
apy was completed, and on the next day he was discharged 
in good general condition.
  At present, 12 months after the event, his general condition 
is fairly good (Eastern Cooperative Oncology Group [ECOG] 
score, 1), even though the metastatic renal cell carcinoma 
has advanced. His Hb level and platelet count are 11.7 g/dL 
and 111,000/μL, respectively, and creatinine level is 7.0 
mg/dL.Korean J Hematol 2011;46:45-8.
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DISCUSSION
  MMC has antitumor antibiotic activity and is used as a 
chemotherapeutic agent. It is an alkylating agent, which 
produces DNA cross-links and inhibits DNA and RNA 
synthesis. It has been used to treat a variety of cancers, 
including gastrointestinal, breast, and bladder cancers. 
MMC-induced TTP-hemolytic uremic syndrome (HUS) may 
develop within weeks to months of the last dose of MMC, 
and the overall incidence is related to the cumulative dose 
[3]. The risk of developing TTP-HUS after treatment with 
MMC is 4-15% [4, 5].
  The only requirement for making an initial diagnosis of 
idiopathic TTP-HUS and initiating treatment with plasma 
exchange is the presence of thrombocytopenia and micro-
angiopathic hemolytic anemia [1]. Plasma exchange is the 
most effective treatment for TTP-HUS, and it reduces the 
mortality rate to 13-22% [6]. However, 10-20% of patients 
show a transient, incomplete, or no response to plasma 
exchange. Rituximab should be administered in addition to 
plasma exchange in cases of refractory or recurrent TTP- 
HUS. Scully et al. reported that 25 patients with acute re-
fractory or relapsing idiopathic TTP received rituximab in 
conjunction with plasma exchange [7]. All the patients at-
tained complete remission (CR) in a median of 11 days after 
rituximab administration was initiated. Among the cases of 
acute refractory TTP, the median numbers of plasma ex-
change performed before rituximab administration and after 
the first rituximab infusion were 13 and 9, respectively.
  The prognosis for patients with MMC-induced TTP is 
poor. Most patients die within 4 months of diagnosis, either 
from pulmonary or renal failure or from the underlying 
malignancies [3, 8]. Plasma exchange is ineffective in most 
patients, and no effective therapy has yet been identified. 
Only a few cases have reported that MMC-induced TTP 
has been successfully treated with vincristine and cyclo-
phosphamide therapy and staphylococcal protein A im-
munoadsorption therapy [10, 11]. In addition, one case re-
ported successful treatment of MMC-induced TTP with rit-
uximab [11].
  Our patient presented with dyspnea associated with pul-
monary edema, which progressed to adult respiratory distress 
syndrome (ARDS), as occurs in many patients with MMC-in-
duced TTP [3, 8]. In our case, the cumulative dose of mitomy-
cin was 87 mg. A previous report mentions that in a majority 
of cases, mitomycin-related TTP-HUS developed when the 
patient received a cumulative dose of ≥60 mg, and 58% 
of the cases had received doses of 60-100 mg [3]. Our patient 
was refractory to daily plasmapheresis and concurrent high- 
dose prednisolone for 16 days; however, he began to respond 
slowly to rituximab 375 mg/m
2; a total of 4 doses of rituximab 
were administered on a weekly basis. ARDS was treated 
soon after the initiation of rituximab; it took 5 weeks to 
maintain a platelet count of ≥10,000/μL without platelet 
transfusion. The patient achieved clinical CR, defined by 
Elliott et al., almost 12 months from the date of the first 
dose of rituximab; the normal platelet count was maintained 
for at least 30 days, with the absence of clinical manifestations 
of TTP [12]. Elliott et al. reported that the median number 
of days to achieve CR from the date of the first dose of 
r it u ximab  r ang ed  f ro m 11 days  t o  35 d ays acro s s v ario us  
studies for refractory or relapsing TTP related to ADAMTS13- 
deficiency.
  When his renal cell carcinoma had metastasized to both 
lungs, our patient had received salvage chemotherapy with 
aldesleukin, 5-FU, IFN-α-2b, sorafenib, and MMC. Among 
the anticancer chemotherapeutic agents, MMC and 5-FU 
cause TTP [3]. A dose-response pattern was noted between 
MMC and TTP. However, 5-FU did not reveal a similar 
dose-response pattern, which suggested that 5-FU did not 
have a role in the development of TTP. TTP could develop 
after a few months to several years of IFN-α therapy for 
chronic myeloid leukemia (CML) or chronic hepatitis C 
[13-15].  IFN-α-induced TTP responds well to plasma ex-
change, and the patient recovers spontaneously after dis-
continuation of IFN-α. Therefore, we assumed that TTP 
in our case was attributed to MMC.
  To our knowledge, only a single case has been reported 
in which MMC-induced TTP refractory to plasma exchange 
and prednisone was successfully and promptly treated with 
rituximab [11]. In contrast to that reported in the previous 
case, our patient showed slow response to rituximab treat-
ment but ended up achieving clinical CR despite progressive 
underlying malignancy.
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